Short answer
RECURSION PHARMACEUTICALS, INC. (RXRX) filed its Q1 2026 10-Q quarterly report on May 6, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $6M (down 56.1% year over year) with net income of −$118M.
Q1 2026 key financials · XBRL
- Revenue
- $6M
- −56.1% YoY
- Net income
- −$118M
- +42.0% YoY
- Operating margin
- -1985.6%
- EPS (diluted)
- −$0.22
- +56.0% YoY
Source: XBRL data from the RECURSION PHARMACEUTICALS, INC. (RXRX) Q1 2026 10-Q on SEC EDGAR. USD.
RECURSION PHARMACEUTICALS, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $6.5M, down 56% YoY from $14.7M, driven by lower Roche revenue recognition
- Net loss $117.5M vs $202.5M YoY; operating loss $128.5M vs $191.4M
- Platform R&D largest line at $41.2M, down 40% YoY; clinical R&D $17.6M, essentially flat
- Cash, equivalents and restricted cash $665.2M vs $753.9M at December 31, 2025
- Operating cash outflow $81.1M vs $132.0M YoY; cash sufficient for at least twelve months, additional financing anticipated
Risk Factors
- No risk-factors section provided; submitted text covers unregistered securities, trading arrangements, and exhibits
- Potential dilution from 4,800 stock-option shares issued for approximately $2 thousand
- Insider selling exposure from Rule 10b5-1 plan covering up to 12,735 shares through June 2, 2027
- Financing execution risk from new TD Securities sales agreement dated February 25, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other RECURSION PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.